NASDAQ:PRAX Praxis Precision Medicines Q1 2025 Earnings Report $36.00 0.00 (0.00%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$35.76 -0.24 (-0.68%) As of 04/25/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Praxis Precision Medicines EPS ResultsActual EPSN/AConsensus EPS -$3.20Beat/MissN/AOne Year Ago EPSN/APraxis Precision Medicines Revenue ResultsActual RevenueN/AExpected Revenue$0.18 millionBeat/MissN/AYoY Revenue GrowthN/APraxis Precision Medicines Announcement DetailsQuarterQ1 2025Date5/12/2025TimeBefore Market OpensConference Call DateFriday, May 9, 2025Conference Call Time12:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Praxis Precision Medicines Earnings HeadlinesPraxis Precision Medicine Stock Price, Quotes and Forecasts | NASDAQ:PRAX | BenzingaApril 21, 2025 | benzinga.comPraxis Precision Medicines (NASDAQ:PRAX) vs. Dr. Reddy's Laboratories (NYSE:RDY) Head-To-Head SurveyApril 21, 2025 | americanbankingnews.comTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 27, 2025 | Porter & Company (Ad)Comparing Praxis Precision Medicines (NASDAQ:PRAX) & ABIVAX Société Anonyme (NASDAQ:ABVX)April 20, 2025 | americanbankingnews.comPraxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives $123.33 Average Price Target from BrokeragesApril 17, 2025 | americanbankingnews.comPraxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic EncephalopathiesApril 8, 2025 | globenewswire.comSee More Praxis Precision Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Praxis Precision Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Praxis Precision Medicines and other key companies, straight to your email. Email Address About Praxis Precision MedicinesPraxis Precision Medicines (NASDAQ:PRAX), a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.View Praxis Precision Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Markets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsIs Intuitive Surgical a Buy After Volatile Reaction to Earnings?Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsRocket Lab Lands New Contract, Builds Momentum Ahead of EarningsAmazon's Earnings Could Fuel a Rapid Breakout Upcoming Earnings Cadence Design Systems (4/28/2025)Welltower (4/28/2025)Waste Management (4/28/2025)AstraZeneca (4/29/2025)Mondelez International (4/29/2025)PayPal (4/29/2025)Starbucks (4/29/2025)DoorDash (4/29/2025)Honeywell International (4/29/2025)Regeneron Pharmaceuticals (4/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
